Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Kubista E  
Behandlung klimakterischer Symptome nach Brustkrebs mit Liviel(R) - Die LIBERATE-Studie

Journal für Menopause 2003; 10 (Sonderheft 3) (Ausgabe für Österreich): 16-19

Volltext (PDF)    Summary    Abbildungen   

Abb. 1: Tibolon - Wirkungsprofil Abb. 2: LIBERATE-Studie Abb. 3: LIBERATE-Studie - Studienzentren

Keywords: LIBERATE-StudieLivielMammakarzinomMenopauseOrganon GesmbHTibolon

After and during breast cancer treatment many women develop severe climacteric symptoms. This symptoms are engraved due to the antihormonal or chemotherapeutic agent used for therapy. Estrogen and gestagen containing compounds cannot be used in patients after breast cancer due to the oncologic situation. No studies on this field exist so far. Tibolone has very favourable inhibiting effects in preclinical and clinical studies concerning the growth of breast-cancer-cell-lines and breast tumours. Therefore, a unique international, multicentric prospective randomised trial was started to evaluate the safety and efficacy of tibolone in breast cancer patients in respect to tumour-growth and climacteric symptoms.
copyright © 2003–2018 Krause & Pachernegg GmbH | Sitemap | Impressum